Next-generation microneedle patches for transdermal therapeutics and diagnostics Authors: Tsung-Hsien Chen, Ming-Tse Hsu, Kun-Hua Lee, Riya Karmakar, Arvind Mukundan, Sangamithirai Sridharan Kuzhali, Chu-Kuang Chou, Wen-Shou Lin, Hsiang-Chen Wang Published: 2026 ABSTRACT Microneedle patches (MNPs) have emerged as versatile platforms for minimally invasive transdermal drug delivery, biosensing, and point-of-care diagnostics by transiently breaching the stratum corneum while minimizing pain and tissue damage. Recent advances in biomaterials, microfabrication, additive manufacturing, and bioelectronics have expanded MNP functionality beyond drug delivery to include controlled therapeutic release, interstitial fluid sampling, wearable biosensing, and closed-loop therapeutic systems. However, despite substantial technological progress, clinical translation remains constrained by challenges related to manufacturing scalability, device reproducibility, standardized characterization, quality assurance, regulatory approval, and commercialization. Unlike previous reviews that primarily emphasize microneedle classifications or material platforms, this review provides a critical translational perspective by integrating materials science, engineering, manufacturing, biosensing, and regulatory considerations into a unified framework. Major fabrication strategies, material platforms, and characterization methods are systematically compared with respect to mechanical performance, manufacturability, reproducibility, and clinical applicability. Current therapeutic and diagnostic applications are critically evaluated alongside the key barriers to industrial production and regulatory implementation. Emerging opportunities, including smart biosensing, stimuli-responsive materials, additive manufacturing, and closed-loop therapeutic systems, are also discussed. By highlighting the factors that govern technology readiness and clinical implementation, this review provides practical insights for accelerating the development and commercialization of next-generation microneedle platforms for drug delivery, biosensing, vaccination, and precision medicine. Introduction Conventional drug delivery strategies, including hypodermic injections, oral administration, topical formulations, and transdermal patches, low bioavailability, remain widely used but are limited by poor skin penetration, enzymatic degradation, low bioavailability, formulation instability, pain, tissue injury, and reduced patient compliance [1–5]. These limitations highlight the need for minimally invasive drug delivery platforms that improve therapeutic efficacy, safety, and patient adherence. Microneedle technology has emerged as a promising alternative by transiently breaching the stratum corneum to create microchannels that enable efficient transdermal transport while minimizing pain and tissue damage [6, 7]. Arranged as microneedle patches (MNPs), these microscale needle arrays facilitate self-administered delivery of therapeutics and vaccines, making them attractive for outpatient care, mass immunization, and home-based healthcare [8, 9]. Depending on their operating mechanism, microneedle systems are broadly classified as passive or active, with the latter incorporating external stimuli, such as ultrasound, electric fields, thermal gradients, or electromagnetic radiation, to achieve spatiotemporally controlled drug release and enhanced delivery efficiency [10]. By bypassing the stratum corneum while avoiding deeper tissues, MNPs improve drug bioavailability without first-pass metabolism, offering rapid therapeutic onset, broad molecular compatibility, reduced side effects, and improving patient compliance compared with conventional delivery routes [7, 11–13]. Beyond drug delivery, MNP technologies have rapidly expanded into vaccination, biomarker sampling, biosensing, and medical cosmetology. Recent integration with bioelectronic and electrochemical sensing platforms further enables real-time physiological monitoring and precision diagnostics, highlighting the growing role of microneedles at the interface of therapeutics, diagnostics, and digital health [14–16]. For coated microneedles, coating thickness, uniformity, and reproducibility critically influence drug loading, release kinetics, and therapeutic reliability [17]. Variations in coating quality can lead to inconsistent dose delivery and present significant challenges for manufacturing quality control, regulatory approval, and clinical translation. Although characterization methods—including optical microscopy, scanning electron microscopy (SEM), mass-based analyses, and fluorescence imaging—have been developed to evaluate coating morphology and drug loading, standardized quantitative protocols remain limited. Establishing robust characterization strategies is therefore essential to ensure reproducibility, quality assurance, and successful clinical implementation of coated microneedle platforms [13, 17, 18]. Although numerous reviews have summarized microneedle materials, architectures, fabrication methods, and therapeutic applications, the translational factors governing successful clinical implementation remain insufficiently addressed [17, 19–21]. This review addresses this gap by providing an integrated evaluation of MNP technologies that links engineering innovation with manufacturing readiness, characterization, regulatory science, and commercialization. Rather than merely describing microneedle platforms, this review critically compares fabrication technologies with respect to scalability, reproducibility, technology maturity, and industrial readiness, while systematically evaluating major material platforms in terms of mechanical performance, drug-loading capability, fabrication complexity, clinical applicability, and commercialization potential. In addition, current characterization strategies—including structural, mechanical, functional, and biosensing evaluations—are discussed, with emphasis on standardized assessment protocols for quality assurance and regulatory compliance. Beyond technological advances, this review examines the key challenges associated with clinical translation, including large-scale manufacturing, sterilization, packaging, storage stability, regulatory pathways, and commercialization. Future perspectives are presented with a focus on intelligent microneedle systems, biosensing integration, personalized medicine, and the scientific, engineering, manufacturing, and regulatory barriers that must be overcome for widespread clinical implementation. Specifically, this review aims to: Critically compare microneedle fabrication techniques based on scalability, reproducibility, manufacturing readiness, and industrial feasibility.Evaluate major microneedle material platforms with respect to mechanical performance, drug-loading capability, fabrication complexity, clinical applicability, and commercialization potential.Integrate characterization strategies, manufacturing considerations, regulatory requirements, and commercialization challenges into a unified translational framework to identify the key barriers limiting clinical adoption. Critically compare microneedle fabrication techniques based on scalability, reproducibility, manufacturing readiness, and industrial feasibility. Critically compare microneedle fabrication techniques based on scalability, reproducibility, manufacturing readiness, and industrial feasibility. Evaluate major microneedle material platforms with respect to mechanical performance, drug-loading capability, fabrication complexity, clinical applicability, and commercialization potential. Evaluate major microneedle material platforms with respect to mechanical performance, drug-loading capability, fabrication complexity, clinical applicability, and commercialization potential. Integrate characterization strategies, manufacturing considerations, regulatory requirements, and commercialization challenges into a unified translational framework to identify the key barriers limiting clinical adoption. Integrate characterization strategies, manufacturing considerations, regulatory requirements, and commercialization challenges into a unified translational framework to identify the key barriers limiting clinical adoption. To improve readability, several schematic illustrations are incorporated throughout the review to summarize fabrication technologies, material platforms, characterization strategies, and the translational pathway from laboratory research to clinical implementation. Origins and evolution of microneedle patch technologies Historical development of microneedle patch technologies The fundamental concepts, classifications, and operating principles of microneedles have been comprehensively reviewed elsewhere; therefore, only a concise overview is provided to establish the background for the subsequent translational discussion [22, 23]. The origins of microneedle technology can be traced to the early twentieth century, when Ernst Kromayer employed motor-driven dental burs for dermatological treatment, demonstrating the therapeutic potential of controlled microscale skin disruption [24]. In 1921, the term “microneedle” was introduced to describe microscale glass needles used for cellular manipulation. The concept was subsequently extended to transdermal drug delivery in 1971 through Place’s pioneering patent describing a multi-projection transdermal device coupled with a drug reservoir for local and systemic therapy [25, 26]. Advances in microfabrication during the late 1990s enabled the fabrication of reproducible silicon microneedle arrays capable of penetrating the stratum corneum while minimizing tissue damage, establishing the feasibility of minimally invasive transdermal delivery [19, 27, 28]. Subsequent developments—including dissolving microneedles, hydrogel-forming systems, stimuli-responsive platforms, and 4D-printed microneedles—have progressively expanded microneedle applications from conventional drug delivery to vaccines, gene therapy, biosensing, and closed-loop therapeutic systems [19, 28–35]. Evolution of microneedle platforms Transdermal drug-delivery technologies have evolved through three major generations. First-generation systems comprise conventional passive transdermal patches suitable primarily for small lipophilic molecules. Second-generation technologies employ chemical permeation enhancers or physical approaches, such as ultrasound, electroporation, iontophoresis, and thermal ablation, to transiently disrupt the skin barrier and improve drug transport [36, 37]. Microneedles represent the defining technology of the third generation by enabling precise penetration of the stratum corneum while minimizing pain and tissue injury. This strategy significantly broadens the range of deliverable therapeutics, including biologics, vaccines, nucleic acids, nanoparticles, and macromolecules, while improving delivery efficiency and patient compliance [38]. Microneedle classification and translational perspective Microneedles are commonly classified into solid, coated, hollow, dissolving, and hydrogel-forming systems according to their design and delivery mechanisms [19, 39, 40]. Although these classifications provide a useful conceptual framework, they offer limited guidance for technology selection and clinical implementation because device performance depends on multiple interrelated factors beyond structural design alone [17, 19]. Successful translation of MNP technologies requires the integration of material properties, fabrication strategies, mechanical reliability, drug-loading capability, manufacturing scalability, quality assurance, and regulatory compliance [19, 21]. Accordingly, the subsequent sections move beyond conventional classification-based descriptions by critically comparing fabrication technologies, material platforms, characterization methods, manufacturing readiness, and regulatory considerations from a translational perspective. This framework provides a more comprehensive basis for evaluating the clinical and commercial potential of next-generation microneedle systems [17, 21]. Microneedle drug delivery mechanisms To avoid conceptual ambiguity, it is important to distinguish microneedle architectures from drug-delivery mechanisms, two terms that are frequently used interchangeably despite describing different aspects of microneedle technology [13, 19]. Microneedle architectures refer to the physical device configurations, including solid, coated, hollow, dissolving and hydrogel-forming microneedles, whose performance is determined by material selection, geometry, and fabrication strategies [20, 39]. In contrast, drug-delivery mechanisms describe how therapeutic agents are transported across the skin following microneedle insertion. These mechanisms are generally categorized into four delivery modes: poke-and-patch, coat-and-poke, poke-and-flow, and dissolve-and-release [13, 19]. Although certain architectures are commonly associated with specific delivery modes, these relationships are not exclusive, as delivery performance can be tailored through device design and formulation engineering. In the poke-and-patch approach, solid microneedles create transient microchannels in the stratum corneum, after which a topical formulation diffuses through the disrupted barrier [20, 39]. The coat-and-poke strategy employs drug-coated microneedles that rapidly release their payload following insertion as the coating dissolves in the interstitial fluid (Fig. 1) [13, 19]. In dissolve-and-release systems, biodegradable or water-soluble microneedles encapsulate therapeutic agents and dissolve after insertion, enabling complete drug deposition while eliminating sharps waste. The poke-and-flow mechanism utilizes hollow microneedles (HMNs) to directly infuse liquid formulations into the dermis through pressure-driven flow (Fig. 2). Collectively, these delivery mechanisms provide versatile strategies for localized or systemic administration and represent the fundamental functional principles underlying microneedle-based drug delivery [17, 19]. Fig. 1This diagram illustrates the coat and poke strategy of solid microneedles, showing the sequence of coating, application and its mechanisms This diagram illustrates the coat and poke strategy of solid microneedles, showing the sequence of coating, application and its mechanisms Fig. 2This figure shows the poke and flow strategy using hollow microneedles that deliver drugs through a central bore directly into the skin via fluid injection This figure shows the poke and flow strategy using hollow microneedles that deliver drugs through a central bore directly into the skin via fluid injection Among these approaches, solid microneedles have been extensively investigated as pretreatment devices to enhance transdermal permeability. By transiently disrupting the stratum corneum without reaching deeper dermal tissues, they markedly increase the transport of compounds ranging from small molecules to proteins and nanoparticles [41, 42]. Their performance is influenced by geometric parameters, including needle length, density, aspect ratio, and tip geometry, which collectively determine insertion efficiency, skin recovery, and drug permeability [43]. Representative studies have further demonstrated the feasibility of silicon solid microneedles for reproducible skin penetration and the successful transdermal delivery of insulin in diabetic animal models, supporting the potential of microneedle-mediated delivery for clinically relevant therapeutics [44, 45]. Hollow microneedles HMNs operate through the poke-and-flow mechanism, in which liquid formulations are delivered into the skin via an internal lumen after penetration of the stratum corneum [46]. HMNs have been fabricated from silicon, metals, ceramics, and glass using microfabrication techniques such as photolithography, wet and dry etching, laser micromachining, and, more recently, additive manufacturing [5, 47–51]. Compared with other microneedle platforms, HMNs enable pressure-driven delivery of relatively large drug volumes, making them particularly suitable for biologics, nanoparticles, and other high-molecular-weight therapeutics [52, 53]. Device performance is strongly influenced by needle geometry, including length, lumen diameter, and tip aperture, which collectively determine insertion efficiency and fluid delivery while minimizing pain [28, 54, 55]. HMNs have demonstrated successful intradermal delivery of dyes, cells, nanoparticles, and liquid therapeutics in both preclinical and ex vivo studies, with rapid lymphatic uptake reported for nanoparticle formulations [46, 52, 56, 57]. Despite their high delivery capacity, widespread clinical translation remains constrained by fabrication complexity, fluidic integration, manufacturing scalability, and production cost [58, 59]. Coated microneedles Coated microneedles employ the coat-and-poke mechanism, whereby therapeutics deposited on the needle surface dissolve rapidly after insertion into the skin, enabling immediate intradermal drug release [5, 60, 61]. A comparative summary of mechanical properties across microneedle materials is provided in Table 1. This platform is particularly attractive for rapid-dose administration of peptides, nucleic acids, vaccines, and small-molecule drugs in a minimally invasive, self-administered format (Fig. 3) [17, 62]. Table 1Comparative mechanical performance of microneedles fabricated from diverse material classesMN MaterialTypical Young’s ModulusFracture Strength / RobustnessInsertion ReliabilityKey LimitationsPolymeric MNsLow–moderate(MPa–GPa range)Moderate;material-dependentVariable;formulation-sensitiveLower stiffness;humidity sensitivityMetallic MNsHigh(tens to hundreds of GPa)High;excellent fracture resistanceHigh and reproducibleHigher cost;safety concernsSilicon MNsVery high(~ 100–170 GPa)Brittle;fracture-proneHigh but fragileRisk of breakage;safety issuesCeramic MNsHigh(tens to > 100 GPa)Brittle;limited toughnessModerate–highFabrication complexityAbbreviation: GPa, gigapascal; MNs, Microneedles. MPa, Megapascal Table 1Comparative mechanical performance of microneedles fabricated from diverse material classesMN MaterialTypical Young’s ModulusFracture Strength / RobustnessInsertion ReliabilityKey LimitationsPolymeric MNsLow–moderate(MPa–GPa range)Moderate;material-dependentVariable;formulation-sensitiveLower stiffness;humidity sensitivityMetallic MNsHigh(tens to hundreds of GPa)High;excellent fracture resistanceHigh and reproducibleHigher cost;safety concernsSilicon MNsVery high(~ 100–170 GPa)Brittle;fracture-proneHigh but fragileRisk of breakage;safety issuesCeramic MNsHigh(tens to > 100 GPa)Brittle;limited toughnessModerate–highFabrication complexityAbbreviation: GPa, gigapascal; MNs, Microneedles. MPa, Megapascal Comparative mechanical performance of microneedles fabricated from diverse material classes Low–moderate (MPa–GPa range) Moderate; material-dependent Variable; formulation-sensitive Lower stiffness; humidity sensitivity High (tens to hundreds of GPa) High; excellent fracture resistance Higher cost; safety concerns Very high (~ 100–170 GPa) Brittle; fracture-prone Risk of breakage; safety issues High (tens to > 100 GPa) Brittle; limited toughness Abbreviation: GPa, gigapascal; MNs, Microneedles. MPa, Megapascal Fig. 3This illustration depicts the coat and poke mechanism where the drug coated microneedles penetrate the skin and release their payload upon insertion for rapid transdermal delivery This illustration depicts the coat and poke mechanism where the drug coated microneedles penetrate the skin and release their payload upon insertion for rapid transdermal delivery An important advantage of coated microneedles is the improved storage stability afforded by solid-state drug formulations, making them especially well-suited for intradermal vaccination because antigen delivery to the epidermis and superficial dermis facilitates efficient targeting of antigen-presenting cells and enhances immune responses [17, 62–64]. Recent advances in scalable coating technologies—including spray coating, drawing lithography, electro drawing, continuous liquid interface production, and additive manufacturing (Table 2)—have further improved coating uniformity, reproducibility, and manufacturing potential [65, 66]. Emerging theragnostic platforms integrating drug delivery with imaging functionalities also highlight the expanding versatility of coated microneedles [67]. Table 2Coating methods, base materials, and microneedle architectures for optimized transdermal delivery and stabilityCoatingMethod Base MN MaterialMN TypeMaterialType StructureDip CoatingStainless steelFlat. 700 μm in lengthMolten polymer formulationsThin polymer coating film [65]Titanium340 μm in lengthAqueous polymer solutionsThin polymer coating film [68]Stainless steelFlat.Polymer solutions containing suspended drug particlesComposite coating film with embedded particles [69]Gas Jet DryingSiliconCone, 60 and 90 μm in length.Aqueous polymer solutionsThin polymer coating film [70]SiliconSegments, 110 μm in lengthAqueous polymer solutionsThin polymer coating film [71]Spray CoatingSiliconContour, 280 μm in lengthAqueous polymer solutionsThin polymer coating film [72]SiliconContour, 300 μm in lengthAqueous polymer solutionsResidual coating layers and thin polymer films [73]Ehda ProcessStainless Steel500 μm in length, FlatAqueous polymer solutionsParticle- and fiber-containing surface coatings [74]Ink Jet PrintingPMVE-MA800 μm in lengthAqueous polymer solutionsMicro droplet Film [74]Stainless Steel700 μm in length, FlatAqueous polymer solutionsSpotted and Micro droplet Film [75]PGA800 μm in length, Half conicalAqueous polymer solutionsMicro-droplet Film [66]Abbreviation: MNs, Microneedles; PGA, Poly (glycolic acid); PMVE-MA, Poly (methyl vinyl ether-alt-maleic acid) Table 2Coating methods, base materials, and microneedle architectures for optimized transdermal delivery and stabilityCoatingMethod Base MN MaterialMN TypeMaterialType StructureDip CoatingStainless steelFlat. 700 μm in lengthMolten polymer formulationsThin polymer coating film [65]Titanium340 μm in lengthAqueous polymer solutionsThin polymer coating film [68]Stainless steelFlat.Polymer solutions containing suspended drug particlesComposite coating film with embedded particles [69]Gas Jet DryingSiliconCone, 60 and 90 μm in length.Aqueous polymer solutionsThin polymer coating film [70]SiliconSegments, 110 μm in lengthAqueous polymer solutionsThin polymer coating film [71]Spray CoatingSiliconContour, 280 μm in lengthAqueous polymer solutionsThin polymer coating film [72]SiliconContour, 300 μm in lengthAqueous polymer solutionsResidual coating layers and thin polymer films [73]Ehda ProcessStainless Steel500 μm in length, FlatAqueous polymer solutionsParticle- and fiber-containing surface coatings [74]Ink Jet PrintingPMVE-MA800 μm in lengthAqueous polymer solutionsMicro droplet Film [74]Stainless Steel700 μm in length, FlatAqueous polymer solutionsSpotted and Micro droplet Film [75]PGA800 μm in length, Half conicalAqueous polymer solutionsMicro-droplet Film [66]Abbreviation: MNs, Microneedles; PGA, Poly (glycolic acid); PMVE-MA, Poly (methyl vinyl ether-alt-maleic acid) Coating methods, base materials, and microneedle architectures for optimized transdermal delivery and stability Abbreviation: MNs, Microneedles; PGA, Poly (glycolic acid); PMVE-MA, Poly (methyl vinyl ether-alt-maleic acid) Dissolving microneedles Dissolving microneedles (DMNs) are fabricated from biodegradable or water-soluble polymers that encapsulate therapeutic agents within the needle matrix and dissolve completely after insertion, eliminating sharps waste and reducing the risk of needle-stick injuries [13, 19]. Their favorable safety profiles, high patient acceptability, and ease of self-administration have made DMNs one of the most extensively investigated platforms for transdermal delivery of vaccines, biologics, peptides, and nucleic acid therapeutics [20]. Despite these advantages, several challenges continue to limit clinical translation. Compared with metallic or silicon microneedles, DMNs generally exhibit lower mechanical strength, which may compromise insertion efficiency [19, 39]. Their limited matrix volume also restricts drug-loading capacity, making high-dose administration difficult [13]. Furthermore, polymer stability can be affected by humidity and temperature, emphasizing the importance of formulation optimization, protective packaging, and scalable manufacturing to ensure product quality and long-term storage stability [17, 19]. Materials and fabrication techniques Microneedle performance is strongly influenced by material composition and fabrication strategy, which collectively determine mechanical integrity, drug-loading capacity, dissolution behavior, biocompatibility, manufacturability, and clinical applicability [19–21]. A broad range of materials, including polymers, silicon, metals, ceramics, hydrogels, and composite systems, has therefore been investigated for microneedle fabrication (Fig. 4) [22]. Rather than providing another classification-based description, this section compares major material platforms in relation to their fabrication characteristics, functional performance, scalability, and translational potential. Fig. 4This illustration depicts the type of materials that can used and further classified in the Fabrication technique This illustration depicts the type of materials that can used and further classified in the Fabrication technique Polymeric microneedles Polymeric microneedles have emerged as highly versatile platforms because of their favorable biocompatibility, tunable mechanical properties, relatively low manufacturing cost, and compatibility with scalable processes such as micromolding, casting, and additive manufacturing [76]. Their chemical flexibility also enables the incorporation of small molecules, peptides, proteins, vaccines, and nucleic acids, making polymeric systems particularly attractive for transdermal drug delivery. Depending on polymer chemistry and formulation, polymeric microneedles can be engineered as dissolving, biodegradable, hydrogel-forming, or stimuli-responsive systems. Dissolving and biodegradable polymers DMNs are typically fabricated from water-soluble or biodegradable polymers, including polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), carboxymethyl cellulose, and poly(methyl vinyl ether-co-maleic acid) [9, 44, 77–82]. Following insertion, these materials dissolve or degrade within the skin, enabling local drug deposition while eliminating sharps waste and reducing needle-stick risks. Their compatibility with mild aqueous processing and micromolding is particularly advantageous for temperature-sensitive therapeutics and scalable manufacturing. However, the physicochemical properties of dissolving polymers must be carefully balanced to achieve sufficient mechanical strength for skin penetration while maintaining appropriate dissolution kinetics and drug-loading capacity. Increasing polymer concentration or molecular weight may improve mechanical robustness but can delay dissolution, whereas highly soluble formulations may compromise insertion reliability. Consequently, formulation composition, moisture sensitivity, drug–polymer interactions and packaging conditions are important determinants of product stability and manufacturing consistency [83, 84]. Hydrogel and stimuli-responsive polymers Hydrogel-forming microneedles provide an alternative strategy in which polymer networks remain structurally intact during insertion and subsequently swell upon hydration, forming aqueous pathways for controlled transport of therapeutic agents [85]. This architecture can support sustained delivery and is particularly suitable for macromolecules and biologics. Stimuli-responsive polymeric microneedles further enable drug release in response to specific physiological signals. Glucose-responsive systems, for example, have been investigated for automated insulin delivery feedback-regulated therapeutic administration in response to hyperglycemia [78, 86–90]. Such platforms represent an important transition from passive transdermal delivery toward responsive and closed-loop therapeutic systems. Nevertheless, challenges related to polymer stability, protein bioactivity, response reproducibility, long-term storage, and scalable fabrication remain important barriers to clinical translation [91–93]. Other material platforms Silicon Silicon was among the earliest materials adopted for microneedle fabrication because of its high stiffness, well-established microfabrication technologies, and precise control over needle geometry. Photolithography and etching enable reproducible fabrication of sharp, high-aspect-ratio structures with well-defined dimensions. However, silicon microneedles are relatively brittle and can involve complex and costly manufacturing processes. Concerns regarding mechanical fracture, fabrication yield, and potential residual material further limit their suitability for some clinical applications. Thus, although silicon remains valuable for research and precision microfabrication, its long-term translational potential is closely linked to manufacturing cost, mechanical reliability, and safety considerations [94–96]. Metals Metals such as stainless steel, titanium, and nickel offer high mechanical strength and fracture resistance, making them suitable for repeated insertion and applications requiring robust structural integrity. Metal microneedles can be manufactured using processes including laser micromachining, electroforming, and micromilling, providing considerable flexibility in device geometry [95, 96]. Nevertheless, manufacturing complexity, corrosion, potential hypersensitivity, and the need for surface modification or coating may increase production and regulatory requirements. Metal systems are therefore attractive when mechanical performance is prioritized but may be less advantageous than polymers for fully dissolving or biodegradable applications. Ceramics Ceramic materials, including alumina and related bioceramics, provide high hardness, chemical stability, excellent corrosion resistance, and thermal durability, which can support mechanically robust microneedle structures for specialized biomedical applications [19, 20]. These intrinsic properties make ceramic-based microneedles attractive for applications requiring structural integrity, dimensional stability, and resistance to environmental degradation [19]. However, their inherent brittleness and relatively demanding processing requirements, including challenges in producing sharp and defect-free microscale features, may limit fabrication flexibility and scalability [20, 21]. Consequently, ceramic microneedles remain less extensively investigated than polymeric and metallic platforms for large-scale transdermal drug delivery, although their superior chemical stability and mechanical durability may provide advantages for selected applications where long-term structural reliability is required [17, 19]. Composites Composite microneedles combine two or more material classes to overcome limitations inherent to individual components [19, 20]. Polymer–ceramic, polymer–metal, and nanomaterial-reinforced systems can be engineered to improve mechanical strength, structural flexibility, drug-loading capacity, electrical conductivity, and sensing performance [20]. This design flexibility is particularly relevant to the development of multifunctional microneedles integrating therapeutic delivery with biosensing, physiological monitoring, or diagnostic functions, thereby enabling closed-loop and personalized biomedical applications [17, 19]. However, increasing material complexity can introduce additional challenges related to interfacial compatibility, material consistency, batch-to-batch reproducibility, manufacturing process control, sterilization compatibility, and regulatory evaluation [21]. Therefore, the translational value of composite systems depends on whether their enhanced functional performance can justify the additional manufacturing complexity, cost, and regulatory burden associated with multi-component architectures [17, 19]. Comparative perspective No single material platform simultaneously satisfies all requirements for optimal mechanical performance, drug-loading capacity, biocompatibility, manufacturability, and regulatory compatibility (Table 3) [19]. Silicon and metals generally provide superior mechanical robustness and dimensional precision but may involve higher fabrication complexity, brittleness, or concerns related to residual materials. Polymeric systems offer greater compositional flexibility, improved biocompatibility, and compatibility with scalable manufacturing, although their mechanical strength, moisture sensitivity, and drug-loading capacity may require optimization. Hydrogel and stimuli-responsive systems further expand functional capabilities by enabling sustained or condition-responsive delivery, but their long-term stability and manufacturing reproducibility remain important challenges [19, 20]. Table 3Comparative evaluation of recent microneedle fabrication technologies from a translational manufacturing perspectiveFabrication TechniqueScalabilityTechnology ReadinessReproducibilityPrecisionMaterial CompatibilityCostAdvantagesLimitationscommercialisation PotentialMicromoldingHighHighHighHighPolymers, hydrogelsLowSimple, low cost, excellent batch-to-batch reproducibility, suitable for mass productionMold dependency, limited design flexibilityHighPhotolithographyMediumHighVery HighVery HighSiliconHighExcellent dimensional control and fabrication precisionRequires clean-room facilities, expensive equipmentMediumDeep Reactive Ion EtchingMediumHighVery HighVery HighSiliconHighHigh aspect-ratio structures with excellent reproducibilityHigh fabrication cost and complex processingMediumLaser MicromachiningMediumHighHighHighMetals, polymersHighFlexible fabrication of metallic MNs, rapid prototypingSurface finishing and relatively low throughputMediumHot EmbossingHighHighHighHighThermoplasticsLow–MediumSuitable for high-volume manufacturing with good reproducibilityRestricted to thermoplastic materialsHighDigital Light ProcessingMedium–HighEmergingHighHighPhotopolymersMediumRapid customization, high resolution, complex geometriesLimited printable biomaterials and post-curing requirementsMedium–HighDirect Ink WritingMediumEmergingModerateModerateHydrogels, polymers, compositesMediumMulti-material printing, excellent formulation flexibilityLower resolution and slower fabrication speedMediumContinuous Liquid Interface ProductionHighEmergingHighHighPhotopolymersHighContinuous high-speed printing with smooth surface qualityMaterial limitations and high equipment costMedium–HighElectrochemical Additive ManufacturingLow–MediumEmergingModerateHighConductive metalsHighEnables fabrication of conductive and multifunctional microneedlesEarly-stage technology with limited scalabilityLow–MediumDroplet-born Air BlowingMediumEmergingModerateModerateBiodegradable polymersLowSimple fabrication without molds; suitable for dissolving MNsLimited geometric precision and industrial validationMediumElectrodrawingMediumEmergingModerateModeratePolymeric materialsLowRapid fabrication of high-aspect-ratio microneedlesLimited control over dimensional uniformityMediumElectroplatingMediumMediumHighHighMetalsMediumProduces robust metallic microneedles with good mechanical propertiesMulti-step fabrication and material restrictionsMedium Table 3Comparative evaluation of recent microneedle fabrication technologies from a translational manufacturing perspectiveFabrication TechniqueScalabilityTechnology ReadinessReproducibilityPrecisionMaterial CompatibilityCostAdvantagesLimitationscommercialisation PotentialMicromoldingHighHighHighHighPolymers, hydrogelsLowSimple, low cost, excellent batch-to-batch reproducibility, suitable for mass productionMold dependency, limited design flexibilityHighPhotolithographyMediumHighVery HighVery HighSiliconHighExcellent dimensional control and fabrication precisionRequires clean-room facilities, expensive equipmentMediumDeep Reactive Ion EtchingMediumHighVery HighVery HighSiliconHighHigh aspect-ratio structures with excellent reproducibilityHigh fabrication cost and complex processingMediumLaser MicromachiningMediumHighHighHighMetals, polymersHighFlexible fabrication of metallic MNs, rapid prototypingSurface finishing and relatively low throughputMediumHot EmbossingHighHighHighHighThermoplasticsLow–MediumSuitable for high-volume manufacturing with good reproducibilityRestricted to thermoplastic materialsHighDigital Light ProcessingMedium–HighEmergingHighHighPhotopolymersMediumRapid customization, high resolution, complex geometriesLimited printable biomaterials and post-curing requirementsMedium–HighDirect Ink WritingMediumEmergingModerateModerateHydrogels, polymers, compositesMediumMulti-material printing, excellent formulation flexibilityLower resolution and slower fabrication speedMediumContinuous Liquid Interface ProductionHighEmergingHighHighPhotopolymersHighContinuous high-speed printing with smooth surface qualityMaterial limitations and high equipment costMedium–HighElectrochemical Additive ManufacturingLow–MediumEmergingModerateHighConductive metalsHighEnables fabrication of conductive and multifunctional microneedlesEarly-stage technology with limited scalabilityLow–MediumDroplet-born Air BlowingMediumEmergingModerateModerateBiodegradable polymersLowSimple fabrication without molds; suitable for dissolving MNsLimited geometric precision and industrial validationMediumElectrodrawingMediumEmergingModerateModeratePolymeric materialsLowRapid fabrication of high-aspect-ratio microneedlesLimited control over dimensional uniformityMediumElectroplatingMediumMediumHighHighMetalsMediumProduces robust metallic microneedles with good mechanical propertiesMulti-step fabrication and material restrictionsMedium Comparative evaluation of recent microneedle fabrication technologies from a translational manufacturing perspective From a translational perspective, material selection should therefore be guided by the intended therapeutic application rather than by material properties alone. Key considerations include mechanical reliability, drug-loading requirements, fabrication scalability, batch-to-batch reproducibility, sterilization compatibility, storage stability, quality control, and regulatory requirements. Accordingly, the most promising microneedle platforms are not necessarily those with the highest laboratory performance, but those that achieve an appropriate balance between functional performance and manufacturing readiness. This materials–manufacturing relationship provides an essential basis for evaluating the clinical and commercial potential of next-generation MNP technologies [19]. Applications in diagnostics MNP technologies have emerged as minimally invasive interfaces for interstitial fluid (ISF) sampling, biomarker detection, and continuous physiological monitoring. According to the location of sample analysis, microneedle-based diagnostic systems can be broadly classified as off-device, on-device, and on-microneedle platforms [97]. Off-device systems extract ISF for subsequent external analysis, whereas on-device systems integrate sampling and analytical components within a single platform. On-microneedle systems directly incorporate sensing elements into individual microneedles, enabling localized and potentially real-time detection. This progression reflects the increasing integration of sampling, sensing, and data processing within a single diagnostic interface. Colorimetric microneedle-based diagnostic systems Colorimetric microneedle systems provide simple and low-cost approaches for decentralized and point-of-care (POC) diagnostics. Enzyme-mediated reactions, such as glucose oxidase–based detection, generate chromogenic responses that correlate with analyte concentrations [16, 97]. Integration of HMNs with paper-based analytical components has enabled rapid blood sampling, plasma separation, and multiplexed detection within compact devices [19, 98]. The major advantages of colorimetric platforms include operational simplicity, portability, low cost, and minimal instrumentation requirements, making them particularly attractive for resource-limited settings [16, 99]. However, visual interpretation is susceptible to variations in lighting, temperature, humidity, and user perception, which can compromise quantitative accuracy. Integration with smartphone-based or optical readers and improved calibration strategies may enhance signal quantification and reproducibility, supporting broader application in decentralized diagnostics. Hydrogel-forming microneedles for biomarker sampling Hydrogel-forming microneedles provide minimally invasive interfaces for ISF extraction and biomarker sampling. Commonly used polymers such as PVA and PVP offer favorable biocompatibility and scalable processing, while crosslinking and polymer modification can improve mechanical strength, swelling behavior, and biomarker recovery [44, 45]. These systems have demonstrated the potential to collect protein biomarkers from skin with limited tissue disruption. Hydrogel-forming microneedles can also be integrated with electrochemical sensing elements to enable continuous monitoring. Examples include microneedle-based sensors for pH, glucose, electrolytes, and other physiological parameters [16, 83, 84, 97, 99–101]. Such systems bridge passive biofluid sampling with active biosensing and provide opportunities for prolonged monitoring. Nevertheless, extraction efficiency, sampling kinetics, analyte recovery, and variability in hydrogel swelling remain important determinants of analytical reliability. Optimization of polymer composition, crosslinking density, and microneedle geometry is therefore essential for improving sampling consistency and quantitative performance. Electrochemical and sensor-integrated microneedle platforms Electrochemical microneedle biosensors are among the most advanced diagnostic platforms because they combine minimally invasive ISF access with sensitive and quantitative signal transduction. These systems have been developed for continuous monitoring of glucose, lactate, electrolytes, and other clinically relevant biomarkers, providing an attractive alternative to repeated blood sampling [102, 103]. A major advance is the integration of microneedle sensing with automated therapeutic systems. For example, glucose-responsive microneedle platforms have been coupled with micropumps to enable feedback-controlled insulin delivery, demonstrating the potential of microneedles to function as integrated sensing–therapy interfaces [104]. Such systems represent a transition from passive biomarker monitoring toward closed-loop and personalized healthcare. Despite their potential, sensor-integrated microneedles remain constrained by fabrication complexity, electrode stability, signal drift, calibration, power requirements, and long-term biocompatibility. Addressing these challenges will be critical for achieving reliable continuous monitoring and clinical translation. Comparative perspective of microneedle-based biosensors Microneedle biosensors employ diverse signal-transduction strategies, most notably electrochemical, colorimetric, and surface-enhanced Raman spectroscopy (SERS) approaches [16, 83, 84, 97, 99–103, 105]. These modalities exhibit distinct trade-offs in analytical performance and translational feasibility. Electrochemical systems provide high sensitivity, quantitative analysis, and compatibility with continuous monitoring but require more complex electrode integration, calibration, and power management. Colorimetric systems offer low-cost, instrument-free or minimally instrumented diagnostics and are particularly suitable for POC applications, although their sensitivity and quantitative accuracy are generally lower. SERS-based platforms provide high chemical specificity, excellent sensitivity, and potential multiplexed detection through plasmonic nanostructures, but their fabrication complexity, signal reproducibility, and dependence on specialized instrumentation remain barriers to widespread implementation. Overall, the development of microneedle diagnostics is progressing from simple biofluid extraction toward integrated, wearable, and potentially closed-loop systems. Future platforms will require simultaneous optimization of analytical sensitivity, sampling efficiency, mechanical reliability, signal stability, manufacturing scalability, and user compatibility. A translational emphasis on standardized performance metrics and reproducible manufacturing will be essential for advancing microneedle biosensors from proof-of-concept demonstrations toward clinically deployable diagnostic technologies. A comparative summary of representative diagnostic microneedle platforms is provided in Table 4. Table 4Key performance metrics of diagnostic microneedle platformsDiagnostic MN PlatformSensitivityLimit of DetectionSampling VolumeResponse TimeISF sampling MNs(off-device)ModerateModerateHigh(µL range)MinutesOn-device MN diagnosticsModerate–highLowModerateMinutesOn-MN sensing platformsHighVery lowLow(nL–µL)Seconds–minutesElectrochemical MN biosensorsHighLow–very lowLowReal-time/ minutesColorimetric MN biosensorsLow–moderateModerateLow–moderateMinutesSERS-based MN sensorsVery highUltra-lowVery lowMinutesAbbreviation: ISF, interstitial fluid; MNs, Microneedles; SERS, surface-enhanced Raman spectroscopy Table 4Key performance metrics of diagnostic microneedle platformsDiagnostic MN PlatformSensitivityLimit of DetectionSampling VolumeResponse TimeISF sampling MNs(off-device)ModerateModerateHigh(µL range)MinutesOn-device MN diagnosticsModerate–highLowModerateMinutesOn-MN sensing platformsHighVery lowLow(nL–µL)Seconds–minutesElectrochemical MN biosensorsHighLow–very lowLowReal-time/ minutesColorimetric MN biosensorsLow–moderateModerateLow–moderateMinutesSERS-based MN sensorsVery highUltra-lowVery lowMinutesAbbreviation: ISF, interstitial fluid; MNs, Microneedles; SERS, surface-enhanced Raman spectroscopy Key performance metrics of diagnostic microneedle platforms ISF sampling MNs (off-device) High (µL range) Low (nL–µL) Abbreviation: ISF, interstitial fluid; MNs, Microneedles; SERS, surface-enhanced Raman spectroscopy Characterization strategies and standardization Comprehensive characterization is essential for ensuring the safety, performance, reproducibility, and clinical translatability of MNP technologies. Although significant progress has been made in the development of diverse microneedle platforms, considerable variability in fabrication methods, material properties, and evaluation protocols continues to hinder meaningful comparisons among studies. Therefore, standardized characterization strategies are increasingly recognized as a prerequisite for regulatory approval, large-scale manufacturing, and successful clinical implementation [19]. A systematic characterization workflow should encompass multiple aspects of microneedle performance, beginning with structural and morphological evaluation. SEM, optical microscopy, and atomic force microscopy are commonly employed to assess needle geometry, tip sharpness, surface roughness, dimensional uniformity, and fabrication accuracy. These analyses provide critical information regarding manufacturing precision and directly influence insertion efficiency and mechanical reliability [20, 21]. Mechanical characterization is equally important because microneedles must possess sufficient strength to penetrate the stratum corneum without fracture or excessive deformation. Compression, bending, fracture, and fatigue tests are widely performed to evaluate structural integrity under clinically relevant loading conditions. Finite element analysis has also emerged as a valuable computational tool for predicting stress distribution, insertion behavior, and structural optimization prior to experimental validation [19, 21]. Following mechanical evaluation, skin insertion performance should be assessed using both ex vivo and in vivo models. Histological analysis, optical coherence tomography, dye staining, and insertion force measurements provide quantitative evidence of penetration depth, insertion efficiency, tissue disruption, and microchannel formation. These techniques are particularly important for correlating microneedle geometry with transdermal delivery performance and minimizing tissue damage [19, 106]. Functional characterization should subsequently evaluate the intended biomedical application of the microneedle platform. For drug-delivery systems, key performance indicators include drug loading efficiency, release kinetics, dissolution behavior, and delivery efficiency. For diagnostic microneedles, characterization should focus on interstitial fluid extraction efficiency, biomarker recovery, sensing accuracy, sensitivity, selectivity, response time, and long-term operational stability. These functional assessments determine whether the device satisfies the requirements for therapeutic or biosensing applications [19, 106]. Beyond laboratory performance, quality assurance and manufacturing reproducibility have become increasingly important for clinical translation. Batch-to-batch consistency, process validation, sterilization compatibility, storage stability, packaging reliability, and compliance with Good Manufacturing Practice (GMP) guidelines are all essential for ensuring product reliability and regulatory acceptance. Establishing standardized testing protocols and internationally accepted evaluation criteria will facilitate cross-study comparisons, improve manufacturing consistency, and accelerate commercialization (Fig. 5) [19, 21]. Collectively, these standardized characterization strategies establish the foundation for the successful clinical translation of MNP technologies. Building upon these evaluation frameworks, the following sections discuss emerging directions that will further accelerate the development of next-generation intelligent microneedle systems [19, 106]. Fig. 5Comprehensive characterization workflow for microneedles Comprehensive characterization workflow for microneedles Future directions and scope Despite substantial progress in microneedle materials, fabrication, drug delivery, and biosensing, clinical translation remains constrained by limited manufacturing scalability, insufficient standardization, and incomplete regulatory and long-term safety frameworks [22, 23]. Future development should therefore move beyond proof-of-concept performance toward integrated evaluation of manufacturability, reproducibility, quality assurance, clinical safety, and regulatory readiness. Additive manufacturing and personalized microneedles Additive manufacturing, particularly three-dimensional (3D) printing, is emerging as an enabling technology for customized microneedle architectures and patient-specific drug delivery. Techniques such as direct ink writing and digital light processing allow precise control of geometry, composition, and spatial drug distribution, facilitating combination therapy and complex device designs [107, 108]. Stimuli-responsive materials can further be integrated with printed structures to achieve controlled, and on-demand release [109]. DLP-based and other advanced printing approaches have also enabled microneedles adapted to curved anatomical surfaces and multifunctional devices that combine therapeutic delivery with sensing capabilities [83, 84, 110–112]. Beyond drug delivery, additive manufacturing enables the integration of microfluidic channels, conductive structures, and biosensing elements into microneedle platforms. Bioinspired architectures can facilitate interstitial-fluid sampling and biomarker detection, while printed conductive microneedles provide opportunities for electrophysiological monitoring [113, 114]. However, improvements in printing resolution and functional integration must be accompanied by advances in production throughput, material consistency, dimensional reproducibility, and quality control to support clinical-scale manufacturing. Smart and Stimuli-Responsive Microneedle Systems The next generation of microneedle platforms is expected to integrate sensing, signal processing, and therapeutic release within a single wearable system. Passive microneedles may evolve toward active biosensing interfaces capable of continuous monitoring of interstitial-fluid biomarkers through electrochemical, colorimetric, SERS, and multiplexed optical strategies [97, 98, 101, 115–119]. In parallel, stimuli-responsive microneedles can regulate drug release in response to external cues, such as near-infrared or ultraviolet irradiation, or endogenous physiological signals, including pH, glucose, and reactive oxygen species [120–122]. The convergence of these functions could enable adaptive therapeutic systems in which biomarker changes directly regulate drug release. Glucose-responsive insulin patches provide an important proof of concept, demonstrating the potential for autonomous, feedback-regulated therapy [34]. Future platforms may incorporate sensing and drug-release microneedles within the same array, coupled with flexible electronics and wireless communication to support continuous monitoring, predictive diagnostics, and personalized treatment. Translational and regulatory priorities Despite rapid technological advances, most multifunctional microneedle systems remain at the preclinical or early proof-of-concept stage (Table 5). Major barriers include limited manufacturing scale, batch-to-batch variability, inadequate long-term safety data, and inconsistent evaluation of insertion force, skin penetration, interstitial fluid extraction, sensing accuracy, and signal stability. The absence of standardized characterization protocols further complicates cross-platform comparison and limits the establishment of clinically meaningful performance benchmarks [19]. Table 5Comparison of Polymeric and Metallic Microneedle PlatformsCharacteristicPolymeric MNsMetallic MNsMechanical strengthModerateHighFracture resistanceModerateExcellentSkin insertionGoodExcellentDrug-loading capacityHighModerate–Low (mainly coated/hollow)Drug releaseSustained / dissolving / controlledRapid releaseBiocompatibilityExcellentGood (material-dependent)BiodegradabilityYesNoManufacturingMicromolding, casting, injection moldingLaser machining, etching, milling, AMScalabilityHighModerateManufacturing costLow–ModerateHighClinical applicationsVaccines, biologics, sustained deliveryFluid extraction, coated delivery, biosensingMajor limitationsLower mechanical strength, moisture sensitivityHigher cost, complex fabrication, regulatory challenges Table 5Comparison of Polymeric and Metallic Microneedle PlatformsCharacteristicPolymeric MNsMetallic MNsMechanical strengthModerateHighFracture resistanceModerateExcellentSkin insertionGoodExcellentDrug-loading capacityHighModerate–Low (mainly coated/hollow)Drug releaseSustained / dissolving / controlledRapid releaseBiocompatibilityExcellentGood (material-dependent)BiodegradabilityYesNoManufacturingMicromolding, casting, injection moldingLaser machining, etching, milling, AMScalabilityHighModerateManufacturing costLow–ModerateHighClinical applicationsVaccines, biologics, sustained deliveryFluid extraction, coated delivery, biosensingMajor limitationsLower mechanical strength, moisture sensitivityHigher cost, complex fabrication, regulatory challenges Comparison of Polymeric and Metallic Microneedle Platforms Clinical translation will therefore require harmonized protocols for mechanical testing, insertion performance, biomarker recovery, analytical validation, biocompatibility, sterilization, storage stability, and long-term dermal safet y. Particular attention is also required for microneedle-based combination products, in which both device performance and therapeutic or diagnostic functionality must satisfy regulatory requirements. Coordinated efforts among academia, industry, and regulatory agencies will be essential to establish reproducible manufacturing processes, robust quality-control strategies, and evidence-based regulatory pathways [17, 21]. Future perspective The long-term potential of MNP technologies lies in the convergence of minimally invasive sampling, continuous biosensing, controlled drug delivery, and digital health. Rather than functioning solely as passive delivery devices, next-generation MNPs may evolve into integrated therapeutic systems capable of sensing physiological changes and adapting treatment in real time. Achieving this transition will require coordinated advances in materials engineering, additive manufacturing, biosensing, flexible electronics, data connectivity, and regulatory science [17]. Importantly, technological sophistication alone will not determine clinical success. Future research should prioritize reproducibility, scalable manufacturing, standardized performance metrics, long-term safety, and patient usability alongside analytical and therapeutic performance. Addressing these engineering and translational requirements will be critical for moving MNP technologies from laboratory-scale demonstrations toward reliable, personalized, and clinically deployable platforms [19, 106]. Clinical translation, regulatory considerations, and commercialization challenges Despite remarkable advances in MNP technologies, their widespread clinical adoption remains limited by challenges spanning manufacturing, quality assurance, regulatory approval, and clinical validation. Although numerous platforms have demonstrated promising preclinical performance, successful translation requires a comprehensive framework that integrates engineering, manufacturing, regulatory science, and evidence-based clinical evaluation [19]. Manufacturing readiness and quality assurance Large-scale manufacturing remains a major barrier to commercialization. Industrial production requires reproducible fabrication, precise dimensional control, consistent drug loading, and high manufacturing yield while maintaining cost-effectiveness and compliance with GMP [19, 21]. Variations in microneedle geometry, mechanical strength, or formulation can directly influence insertion efficiency, drug delivery, and therapeutic outcomes [20]. Accordingly, manufacturing strategies should incorporate Quality-by-Design principles, including the identification of critical quality attributes, critical process parameters, and standardized in-process quality control to improve product consistency and lifecycle management [19, 21]. Product quality also depends on sterilization compatibility, packaging, and storage stability. Sterilization methods, such as gamma irradiation, ethylene oxide sterilization, and electron-beam irradiation, may alter polymer properties, drug stability, or mechanical integrity depending on the material system [13]. Likewise, packaging must protect microneedles against moisture, oxidation, contamination, and mechanical damage throughout storage and distribution, particularly for dissolving and hydrogel-forming formulations that are sensitive to environmental conditions [20]. Clinical validation and regulatory considerations Successful clinical implementation requires robust evaluation under real-world conditions. Patient-related factors, including skin thickness, hydration, anatomical location, age, and disease status, can influence insertion efficiency, drug delivery consistency, and biosensing performance. Although encouraging results have been reported in preclinical studies, multicenter clinical trials with long-term follow-up remain necessary to establish safety, repeated-use reliability, patient acceptability, and therapeutic effectiveness across diverse populations [19]. Regulatory approval presents an additional challenge because microneedle products may be classified as medical devices, pharmaceuticals, biologics, or drug–device combination products depending on their intended use. Consequently, developers must demonstrate material biocompatibility, mechanical reliability, sterility assurance, manufacturing consistency, product stability, and compliance with GMP and internationally recognized quality standards. Early incorporation of regulatory considerations into device development can substantially reduce translational barriers and facilitate commercialization [19]. Standardization and future commercialization A critical limitation in the current literature is the absence of standardized characterization and performance evaluation protocols. Experimental methods for assessing insertion force, fracture resistance, drug release, biosensing accuracy, interstitial fluid extraction, and long-term stability vary considerably across studies, limiting cross-platform comparison and regulatory assessment. The establishment of harmonized testing methodologies and standardized performance metrics would improve reproducibility, support regulatory review, and accelerate industrial translation [17, 21]. Overall, successful commercialization will depend not only on continued advances in materials and device engineering but also on multidisciplinary collaboration among researchers, clinicians, manufacturers, pharmaceutical companies, and regulatory agencies. Future efforts should prioritize scalable manufacturing, standardized characterization, regulatory harmonization, and rigorous clinical validation. Addressing these translational challenges will be essential for enabling the widespread clinical adoption of MNP technologies in drug delivery, vaccination, biosensing, and precision medicine (Table 6; Fig. 6) [17, 19]. Table 6Key challenges and strategies for the clinical translation of microneedle patch technologiesChallengeCurrent LimitationPotential StrategyManufacturing scalabilityLaboratory-scale fabricationHigh-throughput manufacturing, automationBatch-to-batch reproducibilityProcess variabilityQbD, in-line quality controlSterilizationMaterial degradationMaterial-specific sterilization validationStorage stabilityMoisture sensitivityOptimized packaging and stability testingClinical validationLimited long-term dataMulticenter clinical trialsRegulatory approvalComplex combination-product pathwaysEarly regulatory engagement and GMP complianceStandardizationNon-uniform testing methodsHarmonized international testing protocolsCommercialisationHigh production costProcess optimization and cost-effective manufacturingAbbreviation: GMP, Good Manufacturing Practice; QbD, Quality-by-Control Table 6Key challenges and strategies for the clinical translation of microneedle patch technologiesChallengeCurrent LimitationPotential StrategyManufacturing scalabilityLaboratory-scale fabricationHigh-throughput manufacturing, automationBatch-to-batch reproducibilityProcess variabilityQbD, in-line quality controlSterilizationMaterial degradationMaterial-specific sterilization validationStorage stabilityMoisture sensitivityOptimized packaging and stability testingClinical validationLimited long-term dataMulticenter clinical trialsRegulatory approvalComplex combination-product pathwaysEarly regulatory engagement and GMP complianceStandardizationNon-uniform testing methodsHarmonized international testing protocolsCommercialisationHigh production costProcess optimization and cost-effective manufacturingAbbreviation: GMP, Good Manufacturing Practice; QbD, Quality-by-Control Key challenges and strategies for the clinical translation of microneedle patch technologies Abbreviation: GMP, Good Manufacturing Practice; QbD, Quality-by-Control Fig. 6Roadmap for the clinical translation and commercialization of microneedle patch technologies. The successful translation of microneedle systems from laboratory research to clinical implementation requires coordinated progress across multiple stages, including device design, material selection, fabrication, characterization, preclinical evaluation, Good Manufacturing Practice (GMP)-compliant manufacturing, regulatory approval, clinical validation, and commercialization. At each stage, critical challenges—including manufacturing scalability, batch-to-batch reproducibility, sterilization compatibility, storage stability, regulatory compliance, clinical validation, and cost-effectiveness—must be systematically addressed to enable safe, reliable, and commercially viable microneedle products Roadmap for the clinical translation and commercialization of microneedle patch technologies. The successful translation of microneedle systems from laboratory research to clinical implementation requires coordinated progress across multiple stages, including device design, material selection, fabrication, characterization, preclinical evaluation, Good Manufacturing Practice (GMP)-compliant manufacturing, regulatory approval, clinical validation, and commercialization. At each stage, critical challenges—including manufacturing scalability, batch-to-batch reproducibility, sterilization compatibility, storage stability, regulatory compliance, clinical validation, and cost-effectiveness—must be systematically addressed to enable safe, reliable, and commercially viable microneedle products Conclusion This review provides a comprehensive and translational perspective on recent advances in MNP technologies for transdermal drug delivery, biosensing, and minimally invasive diagnostics. Rather than focusing solely on conventional classifications of microneedle types or materials, this review critically compares fabrication strategies, material platforms, characterization methods, manufacturing readiness, and regulatory considerations that collectively determine the clinical and commercial potential of MNP technologies. By integrating engineering, pharmaceutical, manufacturing, and regulatory perspectives, it provides a systematic framework for evaluating the opportunities and limitations associated with next-generation microneedle systems. Recent advances in biomaterials, microfabrication, additive manufacturing, and biosensing have significantly expanded the functionality of microneedle platforms beyond passive transdermal drug delivery. Modern microneedles are increasingly capable of integrating controlled drug release, interstitial-fluid sampling, biomarker sensing, and wearable healthcare technologies, supporting the development of personalized, minimally invasive, and potentially closed-loop therapeutic systems. These technological advances position microneedles as promising platforms for drug delivery, vaccination, point-of-care diagnostics, and precision medicine. Despite this rapid progress, clinical translation remains constrained by several critical challenges. Manufacturing scalability, batch-to-batch reproducibility, standardized characterization, sterilization compatibility, long-term stability, regulatory approval, and comprehensive clinical validation continue to represent major barriers to commercialization [123]. Importantly, successful translation will depend not only on advances in materials and device engineering but also on the establishment of harmonized evaluation protocols, quality assurance strategies, and evidence-based regulatory pathways that enable reliable comparison across different microneedle platforms. Overall, the future success of MNP technologies will depend on multidisciplinary collaboration among materials scientists, biomedical engineers, clinicians, manufacturers, and regulatory agencies. Continued efforts toward scalable manufacturing, standardized testing, regulatory harmonization, and robust clinical validation will be essential for transforming laboratory-scale innovations into safe, reliable, and commercially deployable healthcare products. By bridging engineering innovation with translational and regulatory considerations, MNP technologies are well positioned to become an important enabling platform for next-generation drug delivery, biosensing, vaccination, and precision medicine. Importantly, future progress should be evaluated not only by analytical and therapeutic performance, but also by manufacturing readiness, regulatory compliance, and clinical applicability, which ultimately determine successful translation into healthcare practice.